drugset / Trial / NCT03815929

Oophorectomy, Estrogen Therapy and Cardiovascular Disease Risk in Young Women

NCT03815929

Phase 2 Completed 35 enrolled Mayo Clinic
RandomizedParallel-groupOpen-labelPrevention

Summary

Researchers are trying to assess the appropriate dose of estrogen for decreasing the risk of cardiovascular disease in women who have removal of their ovaries at a young age, before the age of 46 years.

Timeline

Start
2019-03-15
Primary completion
2023-08-28
Completion
2023-08-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Estradiol Other / unclassified 100 ug Other
Comparator Estradiol Other / unclassified Other

Indications

No indication recorded.